Primary Peptides Inc is a clinical-stage targeted protein degradation platform technology company based in Vancouver, Canada. We are developing novel peptide therapeutics using two platform technologies: 1) peptide array for identifying, targeting, and disrupting specific protein-protein interactions; 2) Chaperone-mediated Autophagy Protein Degradation Technology (CHAPTAC) that can compete with small molecule PROTAC technology in degrading proteins of interest and can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision.